ID1 has been previously associated with t(8;21) AML initiation and progression, while the mRNA-destabilizing protein ZFP36L2 has been identified as a critical regulator of AML and potential therapeutic target [33]. This evidence concerns the gene ZFP36L2 and acute myeloid leukemia.